Food & Drug AdministrationFamily PracticeNursingPulmonologyInternal MedicineCritical CareEmergency MedicinePathologyPharmacyPublic HealthFdaInfectious DiseaseCoronavirus
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
THURSDAY, Sept. 3, 2020 (HealthDay News) -- For the second time in days, a Trump appointee to the U.S. Food and Drug Administration has been let go.
John Wagner, who was appointed earlier this summer, no longer heads the agency's office of external affairs, an FDA spokesperson told the Associated Press. Wagner's departure comes after the FDA's mishandling of an announcement about an experimental therapy for COVID-19 that harmed the agency's credibility with the public, according to experts.
Wagner's position will be filled on an acting basis by longtime FDA career official Heidi Rebello, who will oversee all FDA public communications.
A few days ago, communications specialist Emily Miller was removed as the head of the agency's press office, after just 11 days in that position. The Trump appointee helped coordinate the FDA's announcement about granting emergency authorization for the use of convalescent plasma to treat COVID-19 patients, the AP reported.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on May 25, 2022
Read this Next
Other Trending Articles